Inhaled antibiotic for Methicillin-resistant Staphylococcus aureus (MRSA) infections in Cystic Fibrosis (CF) patients.
The company’s lead therapy is dry powder inhalable form of an existing IV antibiotic for the treatment of MRSA in Cystic Fibrosis (CF) patients (and other lung compromised patients). Recent studies have shown that median survival time is shortened for CF patients with MRSA. A Phase 2 trial is now underway and will be completed Q4 2014. Savara intends to exit via IPO or acquisition in 2015.